We are excited to share that Shire and Baxalta have reached an agreement under which Shire will combine with Baxalta.
Shire Chief Executive Officer Flemming Ornskov, M.D., M.P.H, commented: “This proposed combination allows us to realize our vision of building the leading biotechnology company focused on rare disease. Together, we will have leadership positions in multiple, high-value franchises and become the clear partner of choice in rare diseases.”
Baxalta Chairman Wayne T., Hockmeyer, Ph.D., stated, “We launched Baxalta to focus on purpose-driven performance, sustainable growth, and continuing our leadership in developing treatments for orphan and underserved diseases.”
Shire shares that while they are excited about the proposed combination of their two companies, the continuity of their operations will remain uninterrupted. This transaction will not affect their ability to supply existing Shire treatments to patients in need around the world.
Read the press release here: Shire Baxalta Press Release